The Cancer

Don't Miss

How Caregivers Can Assist Liked Ones With Lung Most cancers Really feel in Management

Chris Draft mentioned sufferers with lung most cancers and their caregivers can regain management after analysis by displaying up, staying knowledgeable and leaning into advocacy,...

Household Begins AYA Most cancers Basis After Lymphoma Prognosis

Elaine Riozzi Bodine and her daughter Alayna turned a life-altering analysis right into a mission to help different adolescents and younger adults with most cancers....

Childhood Most cancers Survivors Face Lengthy-Time period Meningioma Danger

Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...

Vital Information

Facts

Latest Articles

A New Choice With out Conventional Chemotherapy for Ph+ ALL

A brand new research suggests {that a} therapy mixture with out conventional chemotherapy ought to turn out to be the brand new...

Jaypirca Matches Imbruvica’s Effectiveness for CLL, With Hints of Lengthy-Time period Profit

Jaypirca (pirtobrutinib) was discovered to have related efficacy as Imbruvica (ibrutinib) in enhancing medical efficacy in sufferers with persistent lymphocytic leukemia (CLL)...

Epkinly Combo Efficient in Second-Line R/R Follicular Lymphoma

Amongst sufferers with relapsed/refractory follicular lymphoma, fixed-duration Epkinly (epcoritamab) plus Rituxan (rituximab) and Revlimid (lenalidomide; R2) was related to important enhancements in...

Azacitidine Plus Venclexta Superior to Chemo in Acute AML

Amongst match sufferers with acute myeloid leukemia, the mix of azacitidine plus Venclexta (venetoclax) was related to a considerably improved event-free survival...

Older Sufferers With DLBCL Could Profit From First-Line Epkinly Plus R-mini-CHOP

Amongst older sufferers with newly identified diffuse massive B-cell lymphoma (DLBCL), remedy with fixed-duration Epkinly (epcoritamab-bysp) plus dose-attenuated Rituxan (rituximab) plus cyclophosphamide,...

Hot Topics